MEDEASE SKIN : Treatment for exzema & atopic dermatitis

Overview

MEDEASE SKIN is a liquid filmogen bandage designed for the treatment of atopic dermatitis such as eczema or dermatitis. It comes in a 50 ml tube and targets pro-inflammatory proteins, contaminants, and impurities.

Targeted Proteins and Actions

The product works through three primary actions:

Protective Barrier Effect

MEDEASE SKIN forms a protective layer on the skin, shielding it from external irritants and allergens that can exacerbate skin conditions like psoriasis, eczema, and dermatitis.

Osmotic and Cleaning Effect

The product helps cleanse the skin of impurities and contaminants, reducing inflammation and promoting healing.

Cellular Repair and Growth Effect

MEDEASE SKIN promotes the repair and growth of skin cells, helping to restore the skin’s natural barrier function and improve its overall health and appearance.

Clinical Trial Results

Clinical trials have shown significant improvements in patients using MEDEASE SKIN. Over a period of 6 weeks, patients experienced a reduction in symptoms such as erythema (76%), edema (74%), oozing (67%), dryness (78%), crusts (64%), and itching (67%). Additionally, the quality of life improved by 60% over 6 weeks. The global mean score related to Eczema and Dermatitis also reduced by 64%, 54.80%, and 65% respectively over 6 weeks.

These results suggest that MEDEASE SKIN could be a promising treatment option for individuals suffering from atopic dermatitis such as eczema, or dermatitis. It provides a multi-faceted approach to skin care, offering protective, cleansing, and healing benefits.

See full publication (PDF)

Main results

• 52 % reduction in erythema over 2 weeks, 76% over 6 weeks
• 54 % reduction in edema over 2 weeks, 74% over 6 weeks
• 48 % reduction in oozing over 2 weeks, 67% over 6 weeks
• 52 % reduction in dryness over 2 weeks, 78% over 6 weeks
• 52 % reduction in dryness over 2 weeks, 78% over 6 weeks
• 32 % reduction of the crusts over 2 weeks, 64% over 6 weeks
• 50 % reduction in itching over 2 weeks, 67% over 6 weeks
• Improvement of the quality of life by 24% over 2 weeks, 60% over 6 weeks.
• 64 % reduction in global mean score related to Psoriasis over 6 weeks.
• 54,80 % reduction in global mean score related to Eczema over 6 weeks.
• 65 % reduction in global mean score related to Dermatitis over 6 weeks.